RT Journal Article
SR Electronic
T1 Side-effects of Pre-operative Epirubicin-Paclitaxel Therapy in Primary Breast Cancer Associated with Tumor Biology
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2675
OP 2680
VO 29
IS 7
A1 WARM, MATHIAS
A1 KATES, RONALD
A1 THOMAS, ANKE
A1 FISCHER, THOMAS
A1 HARBECK, NADIA
YR 2009
UL http://ar.iiarjournals.org/content/29/7/2675.abstract
AB Background: The objective of this analysis is to identify relationships between side-effects, tumor biological factors and response to pre-operative epirubicin and paclitaxel therapy in primary breast cancer. Patients and Methods: The study was completed for 38 primary breast cancer patients (M0) who received pre-operative epirubicin and paclitaxel chemotherapy. Anemia was controlled by epoetin alfa and did not cause deviations from the planned chemotherapy schedule. Results: There were no severe adverse events, cardiotoxicity or neutropenia. Patients with negative estrogen or progesterone receptors, or high KI-67 suffered more alopecia, while HER2 overexpressing patients had less severe nausea. Conclusion: This pre-operative chemotherapy regimen was well tolerated on the whole; side-effect profiles were correlated with tumor biological factors and also with response.